SLATE-ASSET-MANAGEMENT
22.7.2022 08:02:07 CEST | Business Wire | Press release
Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has acquired a majority stake in amperio GmbH (“amperio”), a specialist planner and operator of electric vehicle (“EV”) charging infrastructure in Germany.
Amperio is a leading planner and operator of EV charging stations in the highly-fragmented EV charging market in Germany. Since 2012, amperio has been supporting companies, cities, and communities in developing tailored charging concepts, installing charging stations, and providing backend management services for charging stations. To date, amperio has installed over 1,800 intelligent charging points. Amperio maintains, operates, and executes the billing for over 300 of these charging points on behalf of its customers.
As part of the transaction, Slate created Slate Mobility GmbH & Co. KG (“Slate Mobility”), an entity that will finance and own EV charging equipment for Slate and potential third parties and receive management services from amperio. Slate’s portfolio of over 225 grocery properties across Germany and deep network of relationships with tenants focused on environmental sustainability will create a pipeline of opportunities to accelerate amperio’s growth.
Amperio, together with Move About Groups subsidiary mobileeee GmbH (“mobileeee”) and the City of Ludwigshafen in Germany, are implementing a project for station-based public e-carsharing. The project includes the build-up of 27 stations with mobileeee charging infrastructure as well as publicly accessible charging infrastructure. The City Ludwigshafen initiated this concept with the aim of reducing local emissions in the City and its districts.
“To achieve the German government’s target of having at least 15 million electric cars on the roads by 2030 will require significant investment in EV charging points throughout the country,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Amperio is offering a unique, customizable national product to help meet this demand, backed by a team with a proven track record of experience developing charging infrastructure for cities, communities, and businesses. We are excited to partner with amperio to enhance the sustainability infrastructure of our own properties and improve access to efficient charging points all across Germany.”
“Our partnership with Slate presents an exciting opportunity to scale our business and provide seamless and sustainable mobility solutions that are so urgently needed to protect the climate,” added Oliver P. Kaul, Managing Director of amperio. “Our environment has given us the assignment to create zero-emission mobility. Slate has offered us its properties and the funding to accelerate that mission, which amperio embarked on 10 years ago. Together, we strive to achieve our goal of making clean EV charging technology and services widely available.”
Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. Slate’s most recent impact infrastructure investment was a commitment to Eider VF Limited, a UK-based vertical farming business sustainably growing leafy produce to be sold to the UK mass market.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities.
Visit slateam.com to learn more.
About amperio
amperio GmbH is a specialist planner for charging infrastructure based in Cologne. Since 2012, amperio has been supporting companies, cities and municipalities in developing individual charging concepts, installing charging stations and billing charging processes. In doing so, amperio relies on a holistic service that leaves no customer wishes unfulfilled. This includes location analysis, profitability analysis, business model analysis, technical consulting, backend service (monitoring and billing), the operation of charging points, and energy management and subsidy consulting. In addition, amperio offers two charging infrastructure concepts developed in-house with its CHARGE2GO and Mitarbeiter-Strom products. The company has already installed over 1,800 charging points for customers such as Globus, DKB, Groupe PSA, the city of Düren, Volvo, the city of Bad Ems and the MNT Group.
amperio GmbH is part of Slate Asset Management, a global alternative investment platform, which holds a majority stake in amperio GmbH.
Visit amperio.eu to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005973/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom